Oppenheimer Downgrades Ayala Pharmaceuticals to Perform From Outperform After News of Advaxis Merger Agreement, Price Target Is $16
Oppenheimer Downgrades Ayala Pharmaceuticals to Perform From Outperform After News of Advaxis Merger Agreement, Price Target Is $16
在Advaxis合併協議的消息傳出後，奧本海默將Ayala Pharmicals的評級從跑贏大盤下調至表現，目標股價爲16美元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊